Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma

Xie, Mixue; Huang, Xianbo; Ye, Xiujin; Qian, W.

doi:10.1016/j.intimp.2019.105999

Cited by 54 publications

(40 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High PD1 expression has been demonstrated to predict improved prognosis in patients with breast cancer ( 32 ). A recent study indicated that PD1 has different effects on the prognosis of different subtypes of lymphoma ( 33 ). In the present study, the association between PD1/PD-L1 expression and TACE was also analyzed.…”

Section: Discussionmentioning

confidence: 99%

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

The present study aimed to investigate the effects of transarterial chemoembolization (TACE) on the immune function of patients with hepatocellular carcinoma (HCC). A total of 114 patients with HCC were selected and their peripheral blood was collected before and 1 month after TACE treatment. Flow cytometry and reverse transcription-quantitative PCR were performed to analyze the changes in immune function in patients before and after treatment. Kaplan-Meier curves were plotted for survival analysis. The programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD1) expression before TACE treatment were significantly higher in patients with poor TACE response compared with those patients with well response. Higher PD-L1 mRNA expression in the peripheral blood mononuclear cells after TACE predicted a superior prognosis. After TACE treatment, the proportion of CD4 + /CD8 + cells were decreased while the expression levels of programmed cell death protein 1 (PD1) were significantly increased. To conclude, TACE could reduce the proportion of CD4 + /CD8 + cells and improve the mRNA expression levels of PD1 in patients with HCC. The expression levels of PD1 and PD-L1 were closely related to the therapeutic effect of TACE and the prognosis of patients with HCC. TACE combined with immunotherapy may have potential clinical value for patients with HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Immune checkpoint inhibitor therapy in EBV-associated cancers Overexpression of programmed death ligand 1/2 (PD-L1/2) is a common event in EBV-associated tumors, suggesting the importance of immune evasion in tumorigenesis, which establishes the theoretical basis for the use of immune checkpoint inhibitors in EBV-positive tumors. 29 Preliminary clinical data suggest that PD-1 inhibitors such as nivolumab, pembrolizumab, and avelumab are a promising therapeutic strategy for the treatment of certain EBVassociated tumors, particularly in recurrent or metastatic (R/M) EBVpositive tumors in combination with other treatment methods (e.g., radiotherapy, chemotherapy, or molecular-targeted drugs) showing promising clinical results 392,393 (Table 10). NPC is characterized by high expression of PD-L1 (up to 90% of tumor cells) and a large amount of non-malignant lymphocyte infiltration (about 50% of the sample interstitial TIL > 70% or intratumoral TIL > 10%), making NPC patients suitable for PD-1/PD-L1 immune checkpoint blockade therapy.…”

Section: Ebv-related Vaccinesmentioning

confidence: 99%

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

Cao

Xie

Shi

et al. 2021

Sig Transduct Target Ther

View full text Add to dashboard Cite

Epstein–Barr virus-associated diseases are important global health concerns. As a group I carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial- and lymphatic-originated tumors. Moreover, EBV plays an etiological and pathogenic role in a number of non-neoplastic diseases, and is even involved in multiple autoimmune diseases (SADs). In this review, we summarize and discuss some recent exciting discoveries in EBV research area, which including DNA methylation alterations, metabolic reprogramming, the changes of mitochondria and ubiquitin-proteasome system (UPS), oxidative stress and EBV lytic reactivation, variations in non-coding RNA (ncRNA), radiochemotherapy and immunotherapy. Understanding and learning from this advancement will further confirm the far-reaching and future value of therapeutic strategies in EBV-associated diseases.

show abstract

“…The clinical development of cancer immunotherapies, along with advances in genomic analysis, has validated the important role of TME in predicting cancer response to immune checkpoint blockade therapy (ICB) 13, 57, 58 . We investigate the expression of several inhibitory immune checkpoints between high- and low-risk groups using TMM normalized counts data.…”

Section: Resultsmentioning

confidence: 99%

“…Next, we explored the expression of several inhibitory immune checkpoints between IPI-IPM subgroups so as to predict the response for immunotherapy, where the expression of PD-L1, LAG3 and BTLA were significantly up-regulated in high-risk group. Although PD-L1 expression was shown to correlate with clinical response to PD-1 blockade and prognosis in solid tumors, the expression patterns of PD-1 and PD-L1 are complex and variable in lymphoid malignancies 24,25 . Kim et al has found that high tumoral PD-L1 expression is associated with poor prognosis in primary DLBCL of the central nervous system 26 .…”

Section: Discussionmentioning

confidence: 99%

An IPI based immune prognostic model for diffuse large B-cell lymphoma

Shi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: An enhanced International Prognostic Index (NCCN-IPI) was built to better discriminate diffuse large B-cell lymphoma (DLBCL) patients in the rituximab era. However, there is an urgent need to identify novel valuable biomarkers in the context of targeted therapies, such as immune checkpoint blockade (ICB) therapy. Methods: Gene expression data and clinical information were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. 73 immune-related hub genes in DLBCL patients with different IPI levels were identified by weighted gene co-expression network analysis (WGCNA), and 4 genes were selected to construct an IPI-based immune-related prognostic model (IPI-IPM). Afterward, the genetic, somatic mutational and molecular profiles of IPI-IPM subgroups were analyzed, as well as the potential clinical response of ICB in different IPI-IPM subgroups. Results: The IPI-IPM was constructed base on the expression of LCN2, CD5L, NLRP11 and SERPINB2, where high-risk patients had shorter overall survival (OS) than low-risk patients, consistent with the results in the GEO cohorts. The comprehensive results showed that a high IPI-IPM risk score was correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, high infiltration of CD8+ T cells and macrophages (M1, M2), as well as up-regulation of inhibitory immune checkpoints including PD-L1, LAG3 and BTLA, indicating more potential response to ICB therapy. Conclusion: The IPI-IPM has independent prognostic significance for DLBCL patients, which provides an immunological perspective to elucidate the mechanisms on tumor progression and drug resistance, also sheds a light on developing immunotherapy for DLBCL.

show abstract

Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma

Cited by 54 publications

References 80 publications

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

An IPI based immune prognostic model for diffuse large B-cell lymphoma

Contact Info

Product

Resources

About